Revolution Medicines, Inc. (NAS: RVMDW) Stock Analysis & Fundamentals

RVMDWRevolution Medicines, Inc.

NAS · US · Financial Services · revmed.com

12.27USD+6.88%Mkt Cap: —P/E: —1d ago

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that bind…

Industry Peers

Financial Services

Screen all

BRK-A

Berkshire Hathaway Inc.

$1.07TUSDP/E 12.6

BRK-B

Berkshire Hathaway Inc.

Mastercard Incorporated Class A

$502.58BUSDP/E 31.5

BAC

Bank of America Corporation

The Goldman Sachs Group, Inc.

$297.48BUSDP/E 15.8

PANW

Palo Alto Networks, Inc.

$293.20BUSDP/E 310.1

WFC

Wells Fargo & Company

$259.88BUSDP/E 12.5

AXP

American Express Company

Banco Santander, S.A.

$189.82BUSDP/E 13.9

SAN

Banco Santander, S.A.

$201.87BUSDP/E 13.9

JMG

JPMorgan Emerging Markets Inv Trust

$183.84BUSDP/E 2908.0

ALV

Allianz SE vink.Namens-Aktien o.N.

$180.70BUSDP/E 14.5

The Toronto-Dominion Bank

$194.21BUSDP/E 18.9

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit-1.30B $

Net Income (TTM)-1.13B $

Revenue/Share—

Last Price12.27 USD

Fiscal Year End—

MR Quarter—

Employees883

CountryUS

SectorFinancial Services

Industry—

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B1.01

EPS (TTM)—

EPS (Forward)—

52W Range

1.79098% of range12.53

52W High12.53 USD

52W Low1.790 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-69.35%

ROA-48.05%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-897.74M $

CapEx (TTM)15.99M $

FCF Margin—

FCF Yield—

Net Debt-2.75B $

Net Debt/EBITDA1.70

Balance Sheet

Debt/Equity0.10

Current Ratio11.38

Quick Ratio11.12

Book Value/Sh12.16 USD

Cash/Share18.37 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float184.45M

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta1.40

S&P 52W Chg18.16%

Avg Vol (30d)5.98K

Avg Vol (10d)—

Technical Indicators

RSI (14)88.4

MACD2.4148

MACD Signal1.5695

MACD Hist.+0.8453

BB Upper13.32 USD

BB Middle5.094 USD

BB Lower-3.1307 USD

BB Width322.93%

ATR (14)0.8051 USD

Vol Ratio (20d)4.34x